Genome-Scale DNA Methylome and Transcriptome Profiles of Prostate Cancer Recurrence After Prostatectomy

Jim Smith (), Priyadarshana Ajithkumar, Emma J. Wilkinson, Atreyi Dutta, Sai Shyam Vasantharajan, Angela Yee, Gregory Gimenez, Rathan M. Subramaniam, Michael Lau, Amir D. Zarrabi, Euan J. Rodger () and Aniruddha Chatterjee ()
Additional contact information
Jim Smith: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Priyadarshana Ajithkumar: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Emma J. Wilkinson: Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, TAS 7005, Australia
Atreyi Dutta: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Sai Shyam Vasantharajan: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Angela Yee: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Gregory Gimenez: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Rathan M. Subramaniam: Faculty of Medicine, Nursing & Midwifery and Health Sciences, University of Notre Dame, Sydney, NSW 2000, Australia
Michael Lau: Awanui Labs—Otago Southland, Dunedin 9016, New Zealand
Amir D. Zarrabi: Precision Urology, Mercy Hospital, Dunedin 9010, New Zealand
Euan J. Rodger: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Aniruddha Chatterjee: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand

Data, 2024, vol. 9, issue 12, 1-17

Abstract: Prostate cancer (PCa) is a major health burden worldwide, and despite early treatment, many patients present with biochemical recurrence (BCR) post-treatment, reflected by a rise in prostate-specific antigen (PSA) over a clinical threshold. Novel transcriptomic and epigenomic biomarkers can provide a powerful tools for the clinical management of PCa. Here, we provide matched RNA sequencing and array-based genome-wide DNA methylome data of PCa patients ( n = 17) with or without evidence of BCR following radical prostatectomy. Formalin-fixed paraffin-embedded (FFPE) tissues were used to generate these data, which included technical replicates to provide further validity of the data. We describe the sample features, experimental design, methods and bioinformatic pipelines for processing these multi-omic data. Importantly, comprehensive clinical, histopathological, and follow-up data for each patient were provided to enable the correlation of transcriptome and methylome features with clinical features. Our data will contribute towards the efforts of developing epigenomic and transcriptomic markers for BCR and also facilitate a deeper understanding of the molecular basis of PCa recurrence.

Keywords: prostate cancer; biochemical recurrence; DNA methylation; gene expression; methylationEPIC V2 array; RNA-Seq; epigenetics (search for similar items in EconPapers)
JEL-codes: C8 C80 C81 C82 C83 (search for similar items in EconPapers)
Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2306-5729/9/12/150/pdf (application/pdf)
https://www.mdpi.com/2306-5729/9/12/150/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jdataj:v:9:y:2024:i:12:p:150-:d:1544513

Access Statistics for this article

Data is currently edited by Ms. Cecilia Yang

More articles in Data from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().